With the flow cytometric analysis of the immune cells in the isolated ChP at day 3 post-stroke, CD11b+CD45lo myeloid cells were unchanged between Sham, Veh-treated or ZT-1a-treated ChP, while the number of CD11b+CD45hi myeloid cells increased by 65% in the Veh-treated ChP, compared to the Sham ChP (Fig. 5a, p < 0.01). The gene discussed is ITGAM; the disease is stroke disorder.